
DRTS Stock Forecast & Price Target
DRTS Analyst Ratings
Bulls say
Alpha Tau Medical has made a significant operational advancement by securing a radioactive material license from the New Hampshire Bureau of Public Health Protection, which aligns with the completion of its commercial-scale manufacturing facility in Hudson, NH. This development is expected to facilitate the company's entry into the U.S. market, thereby enhancing its revenue potential beyond its primary base in Israel. Furthermore, the unique capabilities of the Alpha DaRT technology demonstrate promise in addressing unmet needs in oncology and potentially triggering systemic responses, reinforcing the positive outlook for the company’s future prospects.
Bears say
Alpha Tau Medical faces significant risks that could adversely affect its stock, primarily relating to the clinical viability of its AlphaDaRT technology. The potential for failure in clinical trials and the inability to secure regulatory approval in the U.S. presents substantial obstacles to the company's success. Additionally, market limitations, competitive pressures, and the risk of shareholder dilution further exacerbate the uncertainty surrounding Alpha Tau Medical's financial outlook.
This aggregate rating is based on analysts' research of Alpha Tau Medical and is not a guaranteed prediction by Public.com or investment advice.
DRTS Analyst Forecast & Price Prediction
Start investing in DRTS
Order type
Buy in
Order amount
Est. shares
0 shares